A PROMOTER CONSTRUCT FOR GENE EXPRESSION IN NEURONAL CELLS

FIELD OF THE INVENTION

[0001] The invention relates to a promoter construct useful for cell specific gene expression, more particularly expression in neuronal cells.

BACKGROUND OF THE INVENTION

[0002] Neurological illnesses such as stroke, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and many neurogenetic disorders have devastating effects on the individual and result in high social costs associated with chronic care and lost productivity. A common feature of these illnesses is neuronal loss. Many of the aforementioned disorders are related to the absence, malfunction or ineffectiveness of one gene or more and do not respond well to conventional therapeutic means. Gene transfer into the central nervous system (CNS), which involves the delivery and expression of a therapeutic gene, has, therefore, been considered as a potential approach to treatment of these disorders. This approach may mediate expression levels of neurotrophic factors, anti-apoptotic proteins, antioxidant molecules and other therapeutic factors to restore, halt or prevent neuronal degeneration. Gene therapy also offers much hope for the treatment of CNS malignancies.

[0003] The unique characteristics of the CNS, the most sophisticated organ in the body, presents several obstacles to successful gene therapy within the CNS. These characteristics include limited access to the CNS due to the physical barriers of the skull and the blood-brain barrier; the nature of terminally differentiated neurons and the difficulty of efficiently transfecting them with therapeutic genes. Moreover, the cell types found within the CNS are very diverse, many of which are critical to physiological functions and highly sensitive to any kinds of changes. This requires the development of CNS gene therapy that is restricted to a particular type of CNS cell,

thus ensuring therapeutic effects in the desired cells and limiting side effects caused by gene expression in non-target CNS cells.

[0004] Specific gene expression in a selected cell type can be achieved at the level of targeted gene delivery through the use of ligand-associated delivery vectors that bind, via the ligands, to cell surface receptors that are unique to the target cells. Specific gene expression can also be achieved at the level of targeted transcription through the use of cell-specific promoters and enhancers. Cell-specific promoters are one of the primary means through which specialized cellular functions are limited to a particular differentiated cell type. The ability of these promoters to direct transcription of associated genes is regulated by the intracellular concentrations and activities of transcription factors in a specific type of cell.

[0005] Introduction of a transgene into a particular cell can sometimes result in disruption of or interference with cellular functions due to an excess of the transgene product. Due to their specificity, cell-specific promoters may give a level of transcription of a transgene that is acceptable to cellular metabolism, thus avoiding the exhaustion of protein synthesis materials and the over-accumulation of transgene products that may be toxic to transfected cells. Cell-specific promoters, because they are derived from genomic sequences, may also reduce the chance of activating host cell defense machinery and usually are less sensitive to cytokine-induced promoter inactivation than viral promoters. By using a cell-specific promoter, the stability of gene expression is expected to improve. However, the transcriptional activity of cell-specific cellular promoters is often weak, presenting a significant limitation on their use in gene therapy.

SUMMARY OF THE INVENTION

[0006] In one aspect, there is provided a recombinant nucleic acid molecule comprising a neuronal cell specific promoter operably linked to a heterologous enhancer wherein the enhancer is a viral enhancer or promoter and increases the neuronal cell specific transcriptional activity of the promoter. In some embodiments, the promoter is platelet-derived growth factor β-chain promoter and the enhancer is cytomegalovirus

immediate early gene enhancer element. In various embodiments, the recombinant nucleic acid molecule may further comprise an operably linked therapeutic gene coding sequence.

[0006a] In a second aspect, there is provided an expression vector comprising a nucleic acid molecule as defined above.

[0006b] In a third aspect, there is provided a method of expressing a gene in a neuronal cell in culture, said method comprising transforming a neuronal cell with an expression vector as defined above.

[0006c] In a fourth aspect, there is provided the use of an expression vector comprising the recombinant nucleic acid molecule as defined above in the manufacture of a medicament for treating a neuronal disorder in a subject.

[0006d] In a fifth aspect, there is provided a transgenic cell or non-human animal comprising the recombinant nucleic acid molecule as defined above.

[0006e] In a sixth aspect, there is provided a method of increasing the transcriptional activity of a neuronal specific promoter comprising operably linking a heterologous enhancer to the neuronal specific promoter wherein the heterologous enhancer is a viral enhancer or promoter.

[0007] Disclosed is a
method of increasing the transcriptional activity of a neuronal specific promoter comprising operably linking a heterologous enhancer to the neuronal specific promoter.

[0008] In a seventh aspect, there is provided a kit comprising a neuronal cell or cell-line, an expression vector as defined above and instructions to stably transform said cells/cell-lines and express recombinant gene product.

[0008a] In an eighth aspect, there is provided the use of recombinant molecule as defined above in the manufacture of a medicament for the treatment of a neuronal disorder in a subject in need thereof.

[0008b] In a ninth aspect, there is provided the use of an expression vector as defined above in the manufacture of a medicament for the treatment of a neuronal disorder in a subject in need thereof.

[0008c] In a tenth aspect, there is provided a recombinant protein expressed in a neuronal cell or cell-line by transforming the cell or cell-line with the vector as defined above and allowing the transformed cell or cell line to express the recombinant protein.

[0008d] In an eleventh aspect, there is provided the use of the recombinant protein as defined above in the manufacture of a medicament for the treatment of neural disorders.

[0008e] In a twelfth aspect, there is provided a system for increasing transcriptional activity in a neuronal cell or cell-line comprising a neuronal cell-specific promoter operably linked downstream to a heterologous enhancer as substantially described herein.

[0009] Disclosed herein is an expression vector, a transgenic cell and non-human animals comprising a recombinant nucleic acid as defined above. A method of expressing a gene in a neuronal cell comprising transforming a neuronal cell with such an expression vector is also provided.

[0010] Also disclosed herein is a method of treating a neuronal disorder in a subject comprising administering to the subject an expression vector comprising a recombinant nucleic acid molecule described above operably linked to a therapeutic gene coding sequence.

[0011] Further disclosed herein is a method of increasing the transcriptional activity of a neuronal cell specific promoter comprising operably linking a heterologus enhancer to the neuronal cell specific promoter.

FIGURES

[0012] Figure 1. Schematic diagram of the promoter constructs tested in the PGL3 vector: full-length cytomegalovirus promoter (CMV); CMV immediate early gene enhancer (CMVIE); and platelet-derived growth factor β-chain promoter (PDGF-β);

and CMVIE-PDGF-β. The position of the luciferase gene (luc) and the poly A tail (polyA) are also depicted.

[0013] Figure 2. Graphical representation of the luciferase activity levels for each of the promoter constructs, CMV, CMVIE, PDGF-β and CMVIE-PDGF-β driving luciferase expression in neuronal PC12 and MTc17.2 cells after transient transfection. Luciferase activity was expressed in RLU per milligram of protein.

[0014] Figure 3. Photomicrographs of immunohistochemical staining of the rat hippocampus 2 days post-injection of pCMVIE-PDGF-β -luc. The hippocampus sections were stained with antibodies against luciferase protein (red) and the NeuN marker (green).

[0015] Figure 4. High magnification photomicrographs showing double labeling of luciferase (red) with NeuN (green) in the rat striatum at 2 days post-injection of pCMVIE-PDGF-β -luc (a, b, c) and pCMVluc (d, e, f).

[0016] Figure 5. Graphical representation of a time course assay of the average luciferase expression for each plasmid after stereotaxical injection into rat striatum. Values are presented as means + SEM.

[0017] Figure 6. A: Graphical representation of the luciferase activity levels for each of the promoter constructs, CMV, CMVIE, PDGF-β and CMVIE-PDGF driving luciferase expression in rat primary cortex neurons following adeno-associated virus (AAV) and baculovirus mediated transfection. Luciferase activity was expressed in RLU per milligram of protein. B: Graphical representation of a time course assay of the average luciferase expression for each promoter after stereotaxical injection of AAV vectors containing the promoter constructs into rat striatum. Values are presented as means + SEM.

DETAILED DESCRIPTION OF THE INVENTION

[0018] In various aspects, the present invention relates to gene expression and regulation of gene expression. The term "gene" is used in accordance with its usual definition, to mean an operably linked group of nucleic acid sequences.

[0019] The present invention provides a recombinant nucleic acid molecule comprising a chimeric transcription regulatory region that can activate transcription of sequences in neuronal cells when such sequences are operably linked to the regulatory region ("operably linked sequences"). The recombinant nucleic acid molecule of the invention comprises a neuronal cell specific promoter operably linked to a heterologous enhancer wherein the enhancer increases the neuronal cell specific transcriptional activity of the promoter. The terms "neuronal cell" and "neuron", which are used interchangeably herein, in accordance with the usual meaning refer to any conducting cell of the nervous system which typically includes the cell body, several dendrites and the axon. The term "recombinant" means that something has been recombined, such that reference to a recombinant nucleic acid molecule refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques.

[0020] The heterologous enhancer may be any nucleotide sequence which is not naturally operably linked to a neuronal cell specific promoter and which, when so operably linked, increases the neuronal cell specific transcriptional activity of the neuronal cell specific promoter. Reference to increasing the transcriptional activity is meant to refer to any detectable increase in the level of transcription of operably linked sequences compared to the level of the transcription observed with a neuronal cell specific promoter alone, as may be detected in standard transcriptional assays, including using a reporter gene construct as described in the Examples.

[0021] The enhancer therefore comprises at least one nucleotide sequence capable of increasing the neuronal cell specific transcriptional activity of the operably linked

promoter. Generally, enhancers and promoters act to increase and/or activate transcription once bound by appropriate molecules such as transcription factors and the invention therefore encompasses embodiments in which such molecules are provided, either *in vitro* or *in vivo*. For example, and not to limit the invention, eukaryotic transcription factors include, but are not limited to NFAT, AP1, AP-2, Sp1, OCT-I, OCT-2, OAP, NF-κB, CREB, CTF, TFIIA, TFIIB, Pit-I, C/EBP, SRF (Mitchell P J and Tijan R (1989) Science 245:371; Eukaryotic transcription factor-DNA complexes. Patikoglou G, Burley SK. Annu Rev Biophys Biomol Struct 1997; 26:289-325.). In some embodiments, the nucleotide sequence effective to increase the transcriptional activity will retain the minimum binding site(s) for transcription factor(s) required for the sequence to act as an enhancer. As may be necessary to increase trascription of operably linked sequences to the desired extent, in some embodiments, the recombinant nucleic acid may comprise multiple copies of the same sequence or two or more different nucleotide sequence each of which is effective to increase the transcription. For various enhancers which may be used, transcription factor binding sites may be known or identified by one of ordinary skill using methods known in the art, for example by DNA footprinting, gel mobility shift assays, and the like. The factors may also be predicted on the basis of known consensus sequence motifs.

[0022] The enhancer may be a known strong viral enhancer or promoter element such as Rous sarcoma virus (RSV) promoter (Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A 1982; 79:6777-6781), SV40 promoter (Ghosh PK, Lebowitz P, Frisque RJ, Gluzman Y. Identification of a promoter component involved in positioning the 5' termini of simian virus 40 early mRNAs. Proc Natl Acad Sci U S A 1981; 78:100-104), CMV enhancer or promoter including CMV immediate early (IE) gene enhancer (CMVIE enhancer) (Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 1985; 41:521-530; Niwa H, Yamamura H, Miyazaki J. Efficient selection for high-expression

transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-200; see also U.S. Patent Nos. 5,849,522 and 5,168,062). In a specific embodiment, the enhancer is human CMVIE enhancer and in one embodiment comprises the following sequence representing nucleotides -573 to -187 from the TATA box of the human CMV immediate early gene:

```
  1 CCTGGGTCGA CATTGATTAT TGACTAGTTA TTAATAGTAA TCAATACGGG
 51 GTCATTAGTT CATAGCCCAT ATATGGAGTT CCGCGTTACA TAACTTACGG
101 TAAATGGCCC GCCTGGCTGA CCGCCCAACG ACCCCCGCCC ATTGACGTCA
151 ATAATGACGT ATGTTCCCAT AGTAACGCCA ATAGGGACTT TCCATTGACG
201 TCAATGGGTG GACTATTTAC GGTAAACTGC CCACTTGGCA GTACATCAAG
251 TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA CGGTAAATGG
301 CCCCCTGGCA TTATGCCCAG TACATGACCT TATGGGACTT TCTACTTGGC
351 AGTACATCTA CGTATTAGTC ATCGCTATTA CCATGGT (SEQ ID NO. 9)
```

[0023] The enhancer may also be allelic variants and derivatives (such as deletions, insertions, inversion, substitutions or addition of sequences) of this nucleotide sequence and other known enhancer sequences provided such variants or derivatives increase neuronal cell-specific transcription of operably linked sequences.

[0024] In various embodiments, such variants and derivatives may be substantially homologous in that they hybiridize to the sequence of SEQ ID NO. 9 or other enhancer sequences under moderately or stringent, conditions. Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M $NaHPO_4$, 7% (w/v) sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/0.1% (w/v) SDS at 42°C (see Ausubel, *et al.* (eds), 1989, *Current Protocols in Molecular Biology*, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M $NaHPO_4$, 7% (w/v) SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% (w/v) SDS at 68°C (see Ausubel, *et al.* (eds), 1989, *supra*). Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, *Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York). Generally, stringent conditions are selected to be

about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH. Stringent hybridization may for example be in 5 x SSC and 50% formamide at 42° C and washing in a wash buffer consisting of 0.1 x SSC at 65° C. Washes for stringent hybridization may for example be of at least 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes or 120 minutes.

[0025] The degree of homology between sequences may also be expressed as a percentage of identity when the sequences are optimally aligned, meaning the occurrence of exact matches between the sequences. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman,1981, *Adv. Appl. Math* 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, *J. Mol. Biol.* 48:443, the search for similarity method of Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85: 2444, and the computerised implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence alignment may also be carried out using the BLAST algorithm, described in Altschul *et al.*, 1990, *J. Mol. Biol.* 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at http://www.ncbi.nlm.nih.gov/). In various embodiments, the variants and derivatives may be greater than 50%, 80% to 100%, at least 80%, at least 90% or at least 95% identical as determined using such algorithms.

[0026] The neuronal cell specific promoter may be any nucleotide sequence which functions to activate neuronal cell specific transcription, meaning that the sequence activates transcription of operably linked sequences in a neuronal cell and substantially not in other cell types. A promoter does not substantially activate transcription if the levels of transcription of operably linked sequences in any of those cell types are sufficiently low so as not to affect the physiological functioning of the cell. Neuronal cell specific promoters may include promoters for neuronal genes such as Synapsin I, Neuron-specific enolase, Neurofilament-L and Neuropeptide Y and

promoters specific for particular types of neuronal cells. For example, tyrosine hydroxylase gene promoter (4.8kb 5' UTR) is specific for catecholaminergic and the CNS neurons, dopamine-β-hydroxylase gene promoter is specific for adrenergic and noradrenegic neurons and L7 Purkinje cell protein promoter is specific for retinal rod bipolar neurons. For these and other neuronal cell specific promoters including, D1A dopamine receptor gene promoter, human hypoxanthine phosphoribosyltransferase promoter, SCG10 promoter, Tα1 α-tubulin promoter, aldolase C promoter, beta-tubulin gene promoter, GnRH gene enhancer and promoter, glutamate decarboxylase 65 gene promoter, β-galactoside α1,2-fucosyltransferase gene promoter, neuronal nicotinic acetylcholine receptor β3 gene promoter, GABA(A) receptor delta subunit gene promoter, neuron-specific FE65 gene promoter, N-type calcium channel alpha1B subunit gene promoter and microtubule-associated protein 1B gene promoters, see Harrington CA, Lewis EJ, Krzemien D, Chikaraishi DM. Identification and cell type specificity of the tyrosine hydroxylase gene promoter.Nucleic Acids Res 1987, 15:2363-2384; Coker GT 3rd, Vinnedge L, O'Malley KL; Characterization of rat and human tyrosine hydroxylase genes: functional expression of both promoters in neuronal and non-neuronal cell types. Biochem Biophys Res Commun 1988, 157:1341-1347; Banerjee SA, Hoppe P, Brilliant M, Chikaraishi DM. 5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J Neurosci 1992, 12:4460-4467; Morita S, Kobayashi K, Mizuguchi T, Yamada K, Nagatsu I, Titani K, Fujita K, Hidaka H, Nagatsu T. The 5'-flanking region of the human dopamine beta-hydroxylase gene promotes neuron subtype-specific gene expression in the central nervous system of transgenic mice. Brain Res Mol Brain Res 1993; 17:239-244; Ishiguro H, Kim KT, Joh TH, Kim KS. Neuron-specific expression of the human dopamine beta-hydroxylase gene requires both the cAMP-response element and a silencer region. J Biol Chem 1993; 268:17987-17994; Hoyle GW, Mercer EH, Palmiter RD, Brinster RL. Cell-specific expression from the human dopamine beta-hydroxylase promoter in transgenic mice is controlled via a combination of positive and negative regulatory elements. J Neurosci 1994, 14:2455-2463; Severynse DM, Colapietro AM, Box TL, Caron MG. The human D1A dopamine receptor gene

promoter directs expression of a reporter gene to the central nervous system in transgenic mice. Brain Res Mol Brain Res 1995, 30:336-346; Mouradian MM, Minowa MT, Minowa T. Promoter structure of the human gene coding for the D1A dopamine receptor. Adv Neurol 1993, 60:343-345; Stout JT, Chen HY, Brennand J, Caskey CT, Brinster RL. Expression of human HPRT in the central nervous system of transgenic mice. Nature 1985; 317:250-252; Rincon-Limas DE, Geske RS, Xue JJ, Hsu CY, Overbeek PA, Patel PI. 5'-flanking sequences of the human HPRT gene direct neuronal expression in the brain of transgenic mice. J Neurosci Res 1994; 38:259-267; Schwartz ML, Bruce J, Shneidman PS, Schlaepfer WW. Deletion of 3'-untranslated region alters the level of mRNA expression of a neurofilament light subunit transgene. J Biol Chem 1995; 270:26364-9; Forss-Petter S, Danielson PE, Catsicas S, Battenberg E, Price J, Nerenberg M, Sutcliffe JG. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron 1990; 5:187-197; Twyman RM, Jones EA. Sequences in the proximal 5' flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression. J Mol Neurosci 1997; 8:63-73; Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther 1992; 3:487-499; Wuenschell CW, Mori N, Anderson DJ. Analysis of SCG10 gene expression in transgenic mice reveals that neural specificity is achieved through selective derepression. Neuron 1990; 4:595-602; Mori N, Stein R, Sigmund O, Anderson DJ. A cell type-preferred silencer element that controls the neural-specific expression of the SCG10 gene. Neuron 1990; 4:583-594; Hoesche C, Sauerwald A, Veh RW, Krippl B, Kilimann MW. The 5'-flanking region of the rat synapsin I gene directs neuron-specific and developmentally regulated reporter gene expression in transgenic mice. J Biol Chem 1993; 268:26494-26502; Kilic E, Hermann DM, Kugler S, Kilic U, Holzmuller H, Schmeer C, Bahr M. Adenovirus-mediated Bcl-X(L) expression using a neuron-specific synapsin-1 promoter protects against disseminated neuronal injury and brain infarction following focal cerebral ischemia in mice. Neurobiol Dis 2002; 11:275-284; Gloster A, Wu W, Speelman A, Weiss S, Causing C, Pozniak C, Reynolds B, Chang E, Toma JG, Miller FD. The T alpha 1 alpha-

tubulin promoter specifies gene expression as a function of neuronal growth and regeneration in transgenic mice. J Neurosci 1994; 14:7319-7330; Thomas M, Makeh I, Briand P, Kahn A, Skala H. Determinants of the brain-specific expression of the rat aldolase C gene: ex vivo and in vivo analysis. Eur J Biochem 1993; 218:143-151; Thomas M, Skala H, Kahn A, Tuy FP. Functional dissection of the brain-specific rat aldolase C gene promoter in transgenic mice. Essential role of two GC-rich boxes and an HNF3 binding site. J Biol Chem 1995; 270:20316-20321; Dennis K, Uittenbogaard M, Chiaramello A, Moody SA. Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene. Gene 2002 294:269-277; Waldbieser GC, Minth CD, Chrisman CL, Dixon JE. Tissue-specific expression of the human neuropeptide Y gene in transgenic mice. Brain Res Mol Brain Res 1992; 14:87-93; Lawson MA, Macconell LA, Kim J, Powl BT, Nelson SB, Mellon PL. Neuron-specific expression in vivo by defined transcription regulatory elements of the GnRH gene. Endocrinology 2002; 143:1404-1412; Wolfe A, Kim HH, Tobet S, Stafford DE, Radovick S. Identification of a discrete promoter region of the human GnRH gene that is sufficient for directing neuron-specific expression: a role for POU homeodomain transcription factors. Mol Endocrinol 2002; 16:435-449; Makinae K, Kobayashi T, Kobayashi T, Shinkawa H, Sakagami H, Kondo H, Tashiro F, Miyazaki J, Obata K, Tamura S, Yanagawa Y. Structure of the mouse glutamate decarboxylase 65 gene and its promoter: preferential expression of its promoter in the GABAergic neurons of transgenic mice. J Neurochem 2000; 75:1429-1437l; Hitoshi S, Kusunoki S, Kanazawa I, Tsuji S. Dorsal root ganglia neuron-specific promoter activity of the rabbit beta-galactoside alpha1,2-fucosyltransferase gene. J Biol Chem 1999; 274:389-396; Roztocil T, Matter-Sadzinski L, Gomez M, Ballivet M, Matter JM. Functional properties of the neuronal nicotinic acetylcholine receptor beta3 promoter in the developing central nervous system. J Biol Chem 1998; 273:15131-15137; Luscher B, Hauselmann R, Leitgeb S, Rulicke T, Fritschy JM. Neuronal subtype-specific expression directed by the GABA(A) receptor delta subunit gene promoter/upstream region in transgenic mice and in cultured cells. Brain Res Mol Brain Res 1997; 51:197-211; Zambrano N, De Renzis S, Minopoli G, Faraonio R, Donini V, Scaloni A, Cimino F, Russo T. DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter.

Biochem J 1997; 328:293-300; Kim DS, Jung HH, Park SH, Chin H. Isolation and characterization of the 5'-upstream region of the human N-type calcium channel alpha1B subunit gene. Chromosomal localization and promoter analysis. J Biol Chem 1997; 272:5098-5104 and Liu D, Fischer I. Two alternative promoters direct neuron-specific expression of the rat microtubule-associated protein 1B gene. J Neurosci 1996; 16:5026-5036. Other neuronal specific promoters will be known to persons skilled in the art and suitable promoter/enhancer constructs may be readily determined by standard expression assays, including as described in the Examples.

[0027] The promoter comprises at least one nucleotide sequence capable of activating neuronal cell specific expression of operably linked sequences and in some embodiments the nucleotide sequence will retain the minimum binding site(s) for transcription factor(s) required for the sequence to act as a promoter. In some embodiments, the recombinant nucleic acid comprises multiple copies of the same sequence or two or more different nucleotide sequences each of which is effective to activate the transcription activity. For various promoters which may be used, transcription factor binding sites may be known or identified by one of ordinary skill using methods known in the art as described above.

[0028] Platelet-derived growth factor β-chain (PDGF-β) promoter (Sasahara M, Fries JW, Raines EW, Gown AM, Westrum LE, Frosch MP, Bonthron DT, Ross R, Collins T. PDGF-β-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 1991; 64:217-227) has been shown to be specific for CNS neuronal cells, including dopaminergic neurons and in one embodiment, the neuronal cell specific promoter is PDGF-β promoter. In a specific embodiment, the neuronal specific promoter is human PDGF-β promoter and in one embodiment the neuronal cell specific promoter comprises the following sequence representing nucleotides -1492 to -5 from the transcription start site of the human PDGF-ß gene:

```
  1 CTAGAGGATC CACAGTCTCC TGAGTAGCTG GGACTACAGG AGCTTGTTAC
 51 CACACCCAGC TCCAGTTTAT AAATTCATCT CCAGTTTATA AAGGAGGAAA
101 CCGAGGTACT GAGAGGTTAA AAAACCTTCC TGCAGACACT TGTCCAGCAA
151 GTGGCCACTC CAGGATTTGG ACCAAGGTGA TGTGTCTTCA GGCTGTGTCT
201 CTGCCACTGT GCCACGCTGC TGGGTGGTAG GCAGCAGTGG GTGGGTGCCT
251 GCAGTGGTCT GTAAAGACCA CCTGAGATGT CCTTCCTCCT CTGTTCCACC
```

```
 301 CTGTCCAGGT CCAAGAAGAC AGTCTATGAA GAGAGAGCAG GTGTGACTCT
 351 CTCAGTGTGC TCCTCTGTGA GAAGCAGGCT GACATCCCAA AGGGAAGGGC
 401 GGATAACAGA GACAGTGCAA GCGGAGGAGA TGAGGGTGCC TCAAAGCCGG
 451 GAGGCTGGGT GATGCAGGAG CCTGCGTGTC CCGAGGGGGG TGCTGGGCCC
 501 AGTGTGAGTA CGTGTGACTG TGACTGAGAC AGTGTGACTG CTGAAGGCAG
 551 GGACACAGCA GCTCCCTGAC TGGGGGCAGA AGGCGTTAAC TGTGTGAAGG
 601 CTGGTTGTGG GTGGGTGGGC TCTGGGCCTC GAACCCGGGG GCTGAGGGAG
 651 ATAGTAAACA GCAGGGTGAC TGACGGGAAG ATCATGTTGG TAGCCCTGCG
 701 AAGATGCTGC AGGGCTGTGG GGGTTTGTGT GACTTTGCAG TTCAACAAAT
 751 TCAAATTCAG CCAACGCTGG CAGGGCCTGT TGTGCCAGGC AACCAGCTAG
 801 GAGGAGGAGA CTCGGACCCA GCTTGCAGCT GAAGGGCGCT GGCTGCCGGG
 851 TTCTGTGGGT TCACCTTGCG GTGTCTTCCC TTGCTAACAC TGAGTCCTTA
 901 CAATAGCCCC ATCTCCAGGT TGAGGCTAGA TGGAGGGGAC AGAGGGAAGT
 951 GACTTGCCCA AGGTGACCCA AGCTCCCGAG TGCCAGGGCA GGATCTGAAT
1001 TCAGGCTCTC AGACTGCAGA GCCTGAGTCC CTCCCTGCCA TGCCTGTGCC
1051 AGGGTGGAAA TGTCTGGTCC TGGAGGGGAG CGTGGACTCC TGGCCTTGGC
1101 TCTGGAGACA TCCCCCTAGA CCACGTGGGC TCCTAACCTG TCCATGGTCA
1151 CTGTGCTGAG GGGCGGGACG GTGGGTCACC CCTAGTTCTT TTTTCCCCAG
1201 GGCCAGATTC ATGGACTGAA GGGTTGCTCG GCTCTCAGAG ACCCCCTAAG
1251 CGCCCCGCCC TGGCCCCAAG CCCTCCCCCA GCTCCCGCGT CCCCCCCCTC
1301 CTGGCGCTGA CTCCGGGCCA GAAGAGGAAA GGCTGTCTCC ACCCACCTCT
1351 CGCACTCTCC CTTCTCCTTT ATAAAGGCCG GAACAGCTGA AAGGGTGGCA
1401 ACTTCTCCTC CTGCAGCCGG GAGCGGCCTG CCTGCCTCCC TGCGCACCCG
1451 CAGCCTCCCC CGCTGCCTCC CTAGAGTCGA GGAACTAA (SEQ ID NO. 10)
```

[0029] The promoter may also comprise allelic variants and derivatives (such as deletions, insertions, inversion, substitutions or addition of sequences) of this nucleotide sequence and other neuronal cell specific promoter sequences provided such variants or derivatives activate neuronal cell-specific transcription of operably linked sequences. In various embodiments, such variants and derivatives may be substantially homologous as that term is used above, or greater than 50%, 80% to 100%, at least 80%, at least 90% or at least 95% identical as determined using algorithms described above.

[0030] A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the sequences are placed in a functional relationship. For example, a coding sequence is operably linked to a promoter if the promoter activates the transcription of the coding sequence. Similarly, a neuronal cell specific promoter and a heterologous enhancer are operably linked when the enhancer increases the neuronal cell specific transcription of operably linked sequences. Enhancers may function when separated from promoters and as such, an enhancer may be operably linked to a neuronal cell specific promoter but may not be contiguous. Generally, however, operably linked sequences are contiguous.

[0031] In an embodiment of the present invention, CMVIE enhancer is operably linked upstream to PDGF-β promoter. In a further embodiment, CMVIE enhancer is operably linked upstream to PDGF-β promoter and the two sequences are contiguous.

[0032] In an embodiment of the invention, the recombinant nucleic acid molecule comprises the following sequence consisting of SEQ ID NO. 9 upstream of SEQ ID NO. 10 and a linker sequence between SEQ ID NOs. 9 and 10:

5'CCTGGGTCGACATTGATTATTGACTAGTTATTAATAGTAATCAATACGGGGTCATTAGTTCATAGCC
CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC
GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAAT
GGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCC
CTATTGACGTCAATGACGGTAAATGGCCCCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCT
ACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGAGCTCCTAGAGGATCCACAGTCTC
CTGAGTAGCTGGGACTACAGGAGCTTGTTACCACACCCAGCTCCAGTTTATAAATTCATCTCCAGTTTA
TAAAGGAGGAAACCGAGGTACTGAGAGGTTAAAAAACCTTCCTGCAGACACTTGTCCAGCAAGTGGCCA
CTCCAGGATTTGCACCAAGGTGATGTGTCTTCAGGCTGTGTCTCTGCCACTGTGCCACGCTGCTGGGTG
GTAGGCAGCAGTGGGTGGGTGCCTGCAGTGGTCTGTAAAGACCACCTGAGATGTCCTTCCTCCTCTGTT
CCACCCTGTCCAGGTCCAAGAAGACAGTCTATGAAGAGAGCAGGTGTGACTCTCTCAGTGTGCTCCT
CTGTGAGAAGCAGGCTGACATCCCAAAGGGAAGGGCGGATAACAGAGACAGTGCAAGCGGAGGAGATGA
GGGTGCCTCAAAGCCGGGAGGCTGGGTGATGCAGGAGCCTGCGTGTCCCGAGGGGGGTGCTGGGCCCAG
TGTGAGTACGTGTGACTGTGACTGAGACAGTGTGACTGCTGAAGGCAGGGACACAGCAGCTCCCTGACT
GGGGGCAGAAGGCGTTAACTGTGTGAAGGCTGGTTGTGGGTGGGTGGGCTCTGGGCCTCGAACCCGGGG
GCTGAGGGAGATAGTAAACAGCAGGGTGACTGACGGGAAGATCATGTTGGTAGCCCTGCGAAGATGCTG
CAGGGCTGTGGGGGTTTGTGTGACTTTGCAGTTCAACAAATTCAAATTCAGCCAACGCTGGCAGGGCCT
GTTGTGCCAGGCAACCAGCTAGGAGGAGGAGACTCGGACCCAGCTTGCAGCTGAAGGGCGCTGGCTGCC
GGGTTCTGTGGGTTCACCTTGCGGTGTCTTCCCTTGCTAACACTGAGTCCTTACAATAGCCCCATCTCC
AGGTTGAGGCTAGATGGAGGGGACAGAGGGAAGTGACTTGCCCAAGGTGACCCAAGCTCCCGAGTGCCA
GGGCAGGATCTGAATTCAGGCTCTCAGACTGCAGAGCCTGAGTCCCTCCCTGCCATGCCTGTGCCAGGG
TGGAAATGTCTGGTCCTGGAGGGGAGCGTGGACTCCTGGCCTTGGCTCTGGAGACATCCCCCTAGACCA
CGTGGGCTCCTAACCTGTCCATGGTCACTGTGCTGAGGGGCGGGACGGTGGGTCACCCCTAGTTCTTTT
TTCCCCAGGGCCAGATTCATGGACTGAAGGGTTGCTCGGCTCTCAGAGACCCCCTAAGCGCCCCGCCCT
GGCCCCAAGCCCTCCCCCAGCTCCCGCGTCCCCCCCCTCCTGGCGCTGACTCCGGGCCAGAAGAGGAAA
GGCTGTCTCCACCCACCTCTCGCACTCTCCCTTCTCCTTTATAAAGGCCGGAACAGCTGAAAGGGTGGC
AACTTCTCCTCCTGCAGCCGGGAGCGGCCTGCCTGCCTCCCTGCGCACCCGCAGCCTCCCCCGCTGCCT
CCCTAGAGTCGAGGAACTAA3' (SEQ ID NO. 11)

[0033] The recombinant nucleic acid molecule may also comprise at least one operably linked coding sequence. In various embodiments, the operably linked sequence may encode a reporter protein such as luciferase or green fluorescence protein or may be a therapeutic gene sequence.

[0034] In some embodiments, to be operably linked, the neuronal cell specific promoter and the heterologous enhancer may be located on the same strand as the

operably linked sequences and in some embodiments, 5' of the operably linked sequences. In such embodiments, the promoter may be directly 5' of the operably linked sequences or there may be intervening sequences between these regions. In some embodiments the promoter and enhancer may be located 3' of the operably linked sequences. In one embodiment, one or more coding sequences are linked downstream to PDGF-β promoter. In a further embodiment, one or more coding sequences are linked downstream and contiguous to PDGF-β promoter.

[0035] The recombinant nucleic acid molecule of the present invention may be constructed by standard techniques known to one skilled in the art and described, for example, in Sambrook et al. (2001) in Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor, Laboratory Press, and other laboratory manuals. In various aspects of the invention, nucleic acid molecules may be chemically synthesized using techniques such as are disclosed, for example, in Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071. Such synthetic nucleic acids are by their nature "recombinant" as that term is used herein (being the product of successive steps of combining the constituent parts of the molecule).

[0036] In alternative embodiments, isolated nucleic acids may be combined. By isolated, it is meant that the isolated substance has been substantially separated or purified away from other components, such as biological components, with which it would otherwise be associated, for example *in vivo*, so that the isolated substance may itself be manipulated or processed. The term 'isolated' therefore includes substances purified by standard purification methods, as well as substances prepared by recombinant expression in a host, as well as chemically synthesized substances. A promoter is, for example, isolated when it is not immediately contiguous with (i.e., covalently linked to) the coding sequences with which it is normally contiguous in the naturally occurring genome of the organism from which it is derived. A variety of strategies are available for combing or ligating fragments of DNA, and depending on the nature of the termini of the DNA fragments, a suitable strategy will be readily apparent to persons skilled in the art.

[0037] Another aspect of the invention provides an expression vector comprising the recombinant nucleic acid molecule of the invention. The vector may be a plasmid or a virus or virus derived. The construction of such a vector by standard techniques will also be well known to one of ordinary skill in the art. The vectors of the present invention may also contain other sequence elements to facilitate vector propagation and selection in host cells for example, coding sequences for selectable markers, and reporter genes, known to persons skilled in the art. In addition, the vectors of the present invention may comprise a sequence of nucleotides for one or more restriction endonuclease recognition sites.

[0038] In one embodiment, a plasmid expression vector may be constructed by inserting CMVIE enhancer and PDGF-β promoter into the multiple cloning site of the pGL3 plasmid (Promega) as described in the Examples. In the resulting vector, the promoter construct of the invention is operably linked to the luciferase reporter gene contained within the pGL3 plasmid. In some embodiments, a viral expression vector may be constructed by inserting CMVIE enhancer and PDGF-β promoter into AAV and baculovirus as described in the Examples

[0039] An expression vector of the present invention may be introduced into a host cell, which may include a cell capable of expressing the protein encoded by the expression vector. The host cell may include both cultured neuronal cells, including neuronal cell lines, cultured neuronal stem cells and primary neurons, and a neuronal cell within a living organism. Accordingly, the invention also provides host cells containing an expression vector of the invention. The term "host cell" refers not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either cellular differentiation, mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0040] Vector DNA can be introduced into cells by conventional transformation or transfection techniques. The terms "transformation" and "transfection" refer to techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection and viral-mediated transfection. Suitable methods for transforming or transfecting host cells are well known in the art and can for example be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory press (2001)), and other laboratory manuals.

[0041] A cell, tissue, organ, or organism into which has been introduced a foreign nucleic acid, is considered "transformed", "transfected", or "transgenic". A transgenic or transformed cell or organism also includes progeny of the cell or organism and progeny produced from a breeding program employing a transgenic organism as a parent and exhibiting an altered phenotype resulting from the presence of a recombinant nucleic acid construct. A transgenic organism is therefore an organism that has been transformed with a heterologous nucleic acid, or the progeny of such an organism that includes the transgene.

[0042] The invention in various aspects provides a transgenic cell and a non-human animal comprising a recombinant nucleic acid molecule according to various embodiments of the invention.

[0043] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (such as resistance to antibiotics) may be introduced into the host cells along with the gene of interest. Preferred selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acids encoding a selectable marker may be introduced into a host cell on the same vector as that encoding the peptide

compound or may be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid may be identified by drug selection.

[0044] As further described in the examples below, an embodiment of the invention, which combines CMVIE enhancer with PDGF-β promoter, can increase the level of transcription while maintaining neuronal cell specificity, both *in vivo and in vitro*.

[0045] PDGF-β is heavily expressed in neurons of the central nervous system and a PDGF-β promoter fragment has been characterized to target the expression of transgenes to differentiated neurons in transgenic animals. However, PDGF-β promoter is a relatively poor activator of transcription even compared with other neuron-specific promoters.

[0046] In one disclosed embodiment, by combining CMVIE enhancer with PDGF-β promoter, the inventors have been able to achieve for the first time a promoter construct which is specific for neuronal cells and which can activate transcription of operably linked sequences at a higher level and for a longer period than with PDGF-β promoter alone. A recombinant adeno-associated virus vector containing PDGF-β promoter has previously been demonstrated to be able to transduce significantly more dopaminergic neurons than titer-matched vectors carrying CMV promoter. It was therefore surprising that CMVIE enhancer when combined with PDGF-β promoter can increase the level of transcriptional activity in neuronal cells.

[0047] The result was also surprising given that CMV promoter has been shown to be variable in its activities in different cells of the nervous system. A transgene driven by CMV promoter tends to be expressed in the ventricular zone, radial fibers and migrating neuroblasts in the developing brain, but not in mature neurons. This observation is consistent with the finding that CMV infection accounts for little debilitation in adult humans but can be disastrous in the developing human brain, partly due to higher levels of expression of CMV promoter in developing neurons.

Transgenic studies in adult brains of mice have shown restricted expression from CMV promoter in limited types of neurons. A recent paper has reported astrocyte-specific expression when the murine CMV promoter was used. Similarly, baculovirus vectors containing CMV promoter mediated expression primarily in glial cells in adult brains, whereas neuronal expression was observed when the Rous sarcoma virus long terminal repeat (RSV LTR) promoter was used. The variance of these reports is likely related to the observation that slight changes in the CMV promoter sequence generate completely different patterns of expression in CNS neurons. This sequence-specific expression is due in part to the complexity of the CMV promoter that contains binding sites for cAMP, CREB/ATF, NF-κB, SP1, YY1, retinoic acid, AP-1, NF1, its own immediate early protein product, as well as containing a methylation signal sequence.

[0048] It appears, however, when combined with a neuronal cell specific promoter such as PDGF-β promoter, CMVIE enhancer can increase and prolong neuronal cell specific transcription of operably linked sequences. The present invention therefore addresses a major limitation of using a neuronal cell specific promoter in gene therapy.

[0049] While CMVIE enhancer and PDGF-β promoter construct described below illustrates an embodiment of the invention, it will be apparent to those skilled in the art that other constructs may be readily identified by standard expression assays. Each of PDGF-β promoter and CMVIE enhancer when combined with a suitable enhancer or promoter as the case may be can provide a promoter construct that may be suitable for gene expression in neuronal cells. It should also be realized that a combination of CMVIE enhancer and PDGF-β promoter may be used in alternative embodiments. Other suitable neuronal promoters therefore may be identified by combining a promoter which can activate a neuronal cell specific expression with CMVIE enhancer and determining the increase in the expression of operably linked sequences enhancer in neuronal cells. Similarly, other suitable enhancers may be identified by combining a heterologous enhancer with PDGF-β promoter and determining an increase in the expression of operably linked sequences in neuronal

cells. Such other suitable enhancers and promoters may be combined to form other exemplary embodiments of the invention.

[0050] The invention in one aspect provides a method of enhancing the transcriptional activity of a neuronal cell specific promoter comprising operably linking a heterologous enhancer to the neuronal cell specific promoter. In various embodiments, the enhancer and the promoter may be as described above, including human CMVIE enhancer and human PDGF-β promoter. In an embodiment, the enhancer is operably linked upstream to the neuronal cell specific promoter.

[0051] The recombinant nucleic acid molecule, in its various embodiments may be used to express exogenous DNA sequences in neuronal cells, for example to study gene function and regulation of gene expression in neuronal cells.

[0052] High level, long term and cell specific gene expression are required to effectively treat many neurological disorders by gene therapy. The recombinant nucleic acid molecule, in one embodiment, may therefore be advantageously used in gene therapy to treat neuronal disorders, including stroke, ischemia, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and neurogenetic disorders. For example, in Parkinson's disease, a progressive loss of dopaminergic neurons in the substantia nigra ultimately results in a dopamine deficiency and associated motor impairments. An expression vector comprising the CMVIE enhancer and PDGF-β promoter construct therefore should be useful for developing gene therapy for Parkinson's disease that rely on optimal vectors to transfer therapeutic genes into dopaminergic neurons.

[0053] The invention in one aspect provides a method of treating a neuronal disorder in a subject comprising administering to the subject an expression vector comprising the recombinant nucleic acid of the invention operably linked to a therapeutic gene sequence. Therapeutic genes include growth factor genes (which include genes of fibroblast growth factor gene family, nerve growth factor gene

family and insulin-like growth factor genes), and antiapoptotic genes (including genes of bcl-2 gene family).

[0054] Methods for introducing DNA into mammalian cells *in vivo* are known, including for gene therapy and may be used to administer the expression vector DNA of the invention to a subject for gene therapy of neurological disorders. A nucleic acid of the invention may be delivered to cells *in vivo* using methods such as direct injection of DNA, receptor-mediated DNA uptake, viral-mediated transfection or non-viral transfection and lipid based transfection, all of which may involve the use of gene therapy vectors. A delivery apparatus (e.g., a "gene gun") for injecting DNA into cells *in vivo* may be used. Such an apparatus may be commercially available (e.g., from BioRad). In one embodiment, the expression vector is administered by direct injection into the central nervous system or to the cerebrospinal fluid.

[0055] Retrovirus-mediated gene delivery for use as gene therapy has been well characterized and protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), and other standard laboratory manuals. Other known viral vectors for gene therapy include adenovirus and adeno-associated viruses, including for delivery of DNA to cells of the nervous system as described in US patent 6,180,613, and baculovirus-derived vector reported by Sarkis C et al., (Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci U S A 2000 Dec 19; 97:14638-43).

[0056] Where a large amount of DNA may be required to achieve cell-specific gene expression, non-viral, polymeric gene carriers which can incorporate large DNA plasmids may be used as a carrier in gene therapy. These carriers include cationic polymers or lipids as described in Davis ME, Non-viral gene delivery system; Current opinion in biotechnology 2002, 13: 128-131; Niidome T and Huang L, Hene therapy progress and prospects: nonviral vectors. Gene Therapy, 2002, 9:1647-1652; Li S and Huang L, Nonviral gene therapy: promises and challenges. Gene Therapy, 2000, 7:

31-34; Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr J-P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA, 1995; 92: 7297-7302; Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther.1996; 7: 1947-1954; Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, Abdallah B, Demeneix BA. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Therapy, 1998; 5:712-717.

[0057] Plasmid DNA complexed with a cationic polymer such as polyethylenimine (PEI) can be delivered to neuronal cells and in one embodiment, the method of treating a neuronal disorder further comprises the step of mixing the expression vector with a polymeric gene carrier prior to administration. In one embodiment, the polymeric gene carrier is PEI.

[0058] To deliver the vector specifically to neuronal cells in a particular region of the central nervous system, it may be administered by stereotaxic microinjection as is known in the art and as described in the examples. For human patients, the stereotactic frame base will be fixed into the skull and the brain with the stereotactic frame base will be imaged using high resolution MRI. Using appropriate stereotactic software, the images will be translated into 3 dimensional coordinates appropriate for the stereotactic frame for targeted injection of vector DNA.

[0059] All documents referred to herein are fully incorporated by reference.

[0060] Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. All technical and scientific terms used herein have the same meaning as commonly

understood by one of ordinary skill in the art of this invention, unless defined otherwise.

[0061] The word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.

EXAMPLES

1. Materials and Methods

PLASMID CONSTRUCTION

[0062] PGL3-basic vector was purchased from Promega. psubPDGF-EGFP (Paterna *et al.*, 2000) was kindly provided by Prof. H Büeler (Institute of Molecular Biology, University of Zurich, Switzerland). The luciferase constructions of pCMVIE-PDGF-luc, pCMVIEluc, pPDGFluc, pCMVluc were based on pGL3-basic vector. To generate pCMVIE-PDGF-luc, PDGF-β promoter and CMV immediate early (CMVIE) enhancer were amplified from psubPDGF-EGFP and pRc/CMV_2 (Invitrogen life technologies, California, USA) using PCR and inserted between *Sac* I/*Hind* III and *Kpn* I/*Sac* I respectively in the multiple cloning sites of pGL3-basic vector. pCMVIEluc and pPDGFluc were constructed by inserting PCR products of CMVIE enhancer and PDGF promoter into *Kpn* I/*Sac* I and *Sac* I/*Hind* III sites of pGL3-basic vector. To construct pCMVluc, CMV full-length promoter was amplified from pRc/CMV_2 and inserted into *Kpn* I/*Hind* III sites of pGL3-basic vector. Schematic structures of the four different plasmid vectors used in this study are shown in Figure 1.

[0063] All plasmid DNAs were amplified in DH5α *E.coli* and purified according to a standard protocol (Qiagen, Hilden, Germany). Plasmid obtained by PCR amplification were verified by DNA sequencing. Oligonucleotides used for PCR amplification are listed as follows with restriction sites shown in italics.

CMVIE enhancer:

sense primer, 5'- ATTC*GGTACC* CCTGGGTCGACATTGA-3' (SEQ. ID NO. 1)

antisense primer, 5'- CAAC*GAGCTC* ACCATGGTAATAGCGATG-3' (SEQ. ID NO. 2)

CMV promoter:

sense primer, 5'- ATTA*GGTACC* CGATGTACGGGCCAGATATACG-3' (SEQ. ID NO. 3)

antisense primer, 5'- TAAT*AAGCTT* ACTAGTGGATCCGAGCTCGGTA-3' (SEQ. ID NO. 4)

PDGF-β promoter:

sense primer, 5'-AATT*GAGCTC*CTAGAGGATCCACAGTCT-3' (SEQ. ID NO. 5)

antisense primer, 5'-CAGC*AAGCTT*TTCAGTTCCTCGACTCTAG-3' (SEQ. ID NO. 6)

PREPARATION OF DNA/POLYMER COMPLEXES

[0064] Plasmid DNA was diluted in 5% glucose. PEI (25 kDa; Sigma-Aldrich, San Diego, CA) was used as a 10 mM aqueous stock solution. Relative amounts of PEI to DNA for cell transfection and animal experiments were 10 and 14 equivalents of PEI nitrogen per DNA phosphate respectively. The required amount of PEI was calculated by taking into account that 1μg DNA contains 3nmol of phosphate and that 1μl of 10 mM PEI holds 10 nmol of amine nitrogen. Complexes were formed by adding the appropriate amount of PEI solution into the DNA solution, mixing with brief vortex, and waiting for 30 min at room temperature.

PREPARATION OF VIRAL VECTORS

[0065] Recombinant baculoviruses were constructed using the Bac-To-Bac Baculovirus Expression System (Gibco BRL, Life Technologies, Gaithersburg, MD, USA). Luciferase cDNA under the CMV promoter or CMVIE enhancer and PDGF-β promoter were inserted into the transfer plasmid pFastBac1, with the CMV or CMVIE enhancer and PDGF-β promoter inserted between Not1 & Xba1, and luciferase cDNA inserted between Xho1 & HindIII. Recombinant baculoviruses produced were propagated in Sf9 insect cells according to standard methods published by O'Reilly DR, Miller LK, and Luchow VA (Baculovirus Expression Vectors: A Laboratory Manual. New York: W.H. Freeman and Company, 1992). Budded viruses from insect cell culture medium were filtered through a 0.2-*u*m pore size filter and concentrated by ultrafiltration. The viral pellet was resuspended in PBS and infectious titers were determined by plaque assay on Sf9 cells.

[0066] Recombinant adeno-associated viruses (AAV) were constructed using the AAV Helper-Free System (Stratagene, La Jolla, CA). The CMV, PDGF-β and CMVIE enhancer-PDGF-β promoter constructs were inserted into pAAV-luciferase between the Kpn I and Hind III, to generate AAV expression plasmids, pAAV-CMV-luc, pAAV-PDGF-luc and pAAV-CMVIE/PDGF-luc, respectively. All plasmids were amplified in *Escherichia coli* DH5α strain and prepared using Qiagen plasmid Maxi-prep Kit (Qiagen, Ontario, Canada). Recombinant, replication-deficient AAV-2 virions are produced through co-transfection of one of the above three AAV expression plasmid, AAV packaging plasmid pAAV-RC and adenovirus helper plasmid pHelper (1:1:1 molar ratio) in HEK293 cells by PEI method. Three days after transfection, the cells were collected and AAV were released from the cells by two rounds of freeze/thaw cycles. AAV particles were purified by a single-step gravity-flow heparin affinity column, as described by Auricchio A et al. (Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001; 12:71-76). The titers of the purified AAV particles were determined by an ELISA kit from Progen, Germany.

CELL CULTURES

[0067] The *in vitro* transfection experiment was performed in rat pheochromocytoma PC12 cells, neonatal mouse cerebellum stem cells MTC 17.2 and rat primary cortex neurons. MTC 17.2 and primary neurons were grown in DMEM supplemented at 37°C with 10% FBS in an atmosphere of 5% CO_2 and PC12 cells were grown in RPMI 1640 containing 15% FCS.

TRANSFECTION INTO CULTURED CELLS AND LUCIFERASE ACTIVITY ASSAY

[0068] For the transfection of PC12 and MTC 17.2, the cells were split one day prior to transfection and plated in 24-well plates at a cell density of 5×10^4 per well with 0.5 ml of the above indicated medium. After overnight incubation, the culture medium was replaced with 300 µl Opti-MEM and an aliquot of 10 µl of the DNA/PEI complexes containing 0.1 pmole DNA was added to each well of the plates. DNA/PEI complexes were incubated with the cells for 3 hours at 37°C. The medium in each well was replaced with 0.5 ml of fresh complete medium and cells were further incubated for 24 hours. After the incubation, cells were permeabilized with 100 µl of cell lysis buffer (Promega). For the transfection of rat primary cortex neurons, the cells were seeded into 46-well plates for baculovirus infection or 96-well plates for AAV infection. The luciferase activity in cell extracts was measured using a luciferase assay kit (Promega). The relative light units (RLU) were normalized against protein concentration in the cell extracts, which was measured using a protein assay kit (Bio-Rad labs, Hercules, Calif).

IN VIVO STUDY

-Animals

[0069] Adult male Wistar rats (weighing 250-320g) were used in this study. The rats were divided into several groups: for luciferase extraction study, 4 rats were used for each time interval: pCMVIE-PDGF-luc (n = 32), pCMVIEluc (n = 4), pPDGFluc (n = 4), pCMVluc (n = 12); for immunohistochemical study: sham operated group (n = 6), pCMVIE-PDGF-luc injected group (n = 6), pCMVluc injected group (n = 6); for PCR analysis (n = 3). Rats were randomly assigned to each group at various times

after injection. They were kept 4 to a cage in a light-dark cycle (12h/12h) at a constant temperature of 22°C and at 60% humidity, and fed with normal laboratory rat food. In the handling and care of all animals, the International Guiding Principles for Animal Research as stipulated by World Heath Organization (1985) and as adopted by the Laboratory Animal Center, National University of Singapore, were followed. All rats were bred and supplied by the Laboratory Animal Center, National University of Singapore, and kept in the animal unit before and after the experiments.

-Injection procedures

[0070] Rats were anaesthetized by an intraperitoneal injection of sodium pentobarbital (60mg / kg of body weight) and positioned in a stereotaxic instrument with the nose bar set at 0 (for striatum injection) or –3.5 mm (for hippocampus injection). DNA was separately bilaterally injected into the striatum at 3 injection points [coordinates (from bregma and dura): anterior (A), +1.5 mm, lateral (L), +2.0 mm, ventral (V), –5.0 mm; A, +0.5 mm, L, +3 mm, V, -5.0mm and A, -0.3 mm, L, +3 mm, V, -5.0mm] or into the hippocampus (coordinates: A, -4.4 mm, L, +3.2 mm, V, -2.5mm). For each injection, the injection value was 5 µl which contained 1 µg DNA in PEI / DNA complex. The rate of injection was 1 µl / minute and the needle was allowed to remain *in situ* for 5 minutes before being slowly retracted at the end of each injection.

-PCR DETECTION OF LUCIFERASE GENE FROM TISSUE SAMPLES

[0071] Tissue samples of striatum, hippocampus, cortex and substantia nigra were collected from rat brains 2 days after striatum injection of pCMVIE-PDGF-Luc. The tissues were homogenized by mincing with a razor blade and plasmid DNA was extracted according to the standard protocol of a DNAeasy Tissue Kit (Qiagen). The oligonucleotide primers for luciferase PCR are listed below:

5′ primer: 5'-AT TGC TCA ACA GTA TGG GCA-3' (SEQ. ID NO. 7)

3′ primer: 5'-CGA AGA AGG AGA ATA GGG TTG-3' (SEQ. ID NO. 8)

[0072] The expected size of the amplified product is 540 bp. Amplification cycles consisted of 94 °C 5min, 1 cycle; 94 °C, 45 s, 55 °C 30 s, 72 °C, 30 s, 35 cycles with a final extension at 72 °C for 7 min. To exclude contamination of the whole process, a normal rat brain with the injection of PEI was handled in parallel.

-Luciferase assay

[0073] Following deep anesthesia, rats were sacrificed by intracardic perfusion with 0.1 M phosphate buffered saline PBS (pH 7.4). The brains were removed and the four different parts including striatum, hippocampus, cortex and substantia nigra were dissected and separately collected into eppendorf tubes. Tissue samples were stored at -80°C until processing. After adding PBS buffer separately (100 µl PBS per 50 mg tissue), each sample was homogenized by sonication for 10 seconds on ice, and then centrifuged at 13,000 rpm at 4°C in a microcentrifuge. Ten microliters of the supernatant at room temperature was used for the luciferase activity assay employing an assay kit from Promega. Measurements were made in a single-well luminometer (Berthold Lumat LB 9501) for 10 seconds.

-Immunohistochemical analyses

[0074] Two days after injection with pCMVIE-PDGF-luc, pCMVluc or sham operation, rats were sacrificed (n = 3). Following deep anesthesia, all rats were perfused first with Ringer's solution followed by 2% paraformaldehyde in 0.1 M PBS (pH 7.4). After perfusion, the cerebral cortices containing the striatum and hippocampus were removed and post-fixed in the same fixative for 2-4 hours before they were transferred into 0.1 M PBS containing 15% sucrose and kept overnight at 4°C. Frozen coronal sections of each brain were cut at 30µm thickness and collected before being stored in 0.1 M PBS.

[0075] Free-floating sections were washed for 20 min in 0.1M PBS at pH 7.4 containing 0.2% Triton X-100, then blocked with 5% normal goat serum in PBS for 1 hour. Sections were then incubated overnight with primary antibodies: polyclonal anti-luciferase (Promega; dilution 1:150); and monoclonal against neuron-specific

nuclear protein (NeuN) (Chemicon International, USA; dilution 1:500). Sections were washed in 0.1 M PBS and further incubated with anti-rabbit IgG Tritc conjugate (Sigma-Aldrich, Inc., USA; dilution 1:100) and anti-mouse IgG Fitc conjugate (Sigma-Aldrich; dilution 1:100) for 1 hour. After incubation, sections were washed three times in PBS. They were then collected on gelatin-coated slides, mounted with DAKO fluorescent mounting medium and covered with coverslips. Control sections were incubated without primary antibodies.

-Visualization of double labeling with confocal scanning microscopy

[0076] Sections were examined with a Carl Zeiss LSM410 confocal laser scanning microscope. Each section was initially scanned with a 488 nm laser line, and an emission filter BP 510-525, for the detection of Fitc fluorescein; and with a 543 nm laser line, and an emission filter LP 570, for the detection of Tritc fluorescein.

-Quantitative analysis

[0077] Three rats each were used in cell quantification for colocalization of pCMVIE-PDGF-luc and pCMV-luc with NeuN. Four sections for each rat were selected randomly and used for cell counting. A total of 3 bilateral fields selected randomly were surveyed in each section. Each field was captured under a Carl Zeiss LSM410 confocal laser scanning microscope at magnification of 200×. Colocalized cells in each picture were counted and percentages of colocalization of NeuN in pCMVIE-PDGF-luc and pCMV-luc positive cells were calculated respectively. Student's t-test was used to determine the statistical significance of extent of colocalization in different plasmids.

2. Results

[0078] Table 1. The numbers of luciferase immunoreactivity positive cells that contain or lack the neuron-marker NeuN immunoreactivity from rats sacrificed at 2 days post-injection of pCMVIE-PDGF-luc or pCMVluc into either the striatum or the hippocampus.

Injection Sites	Striatum	Hippocampus
Number of Luciferase positive cells per field (Mean ± S.E.M.):		
CMVIE-PDGF	61.17 ± 7.17	31.94 ± 1.58
CMV	106.17 ± 5.89	82.78 ± 4.67
Number of Luciferase and NeuN double labeled cells per field (Mean ± S.E.M.):		
CMVIE-PDGF	55.89 ± 8.37	28.5 ± 2.03
CMV	51.00 ± 2.19	41.78 ± 2.34
Percentage of transfected neurons* (Mean ± S.E.M.):		
CMVIE-PDGF	91.28% ± 4.06%	89.29% ± 2.83%
CMV	48.08% ± 1.08%	50.54% ± 3.46%

* Percentage of transfected neurons = the number of double labeled cells / total number of luciferase immunoreactive cells.

INCREASED IN VITRO GENE EXPRESSION BY USING THE CHIMERIC PROMOTER OF CMVIE-PDGF

[0079] To eliminate the effect of different plasmid backbone on gene expression, all luciferase reporter plasmids were constructed under the same backbone of pGL3-basic vector (Fig. 1). Luciferase expression from pCMVIE-PDGF-Luc was compared *in vitro* with those from pCMVluc, pPDGFluc and pCMVIEluc following the transfection of neuronal cells. As shown in Figure 2, pCMVIE-PDGF-Luc drove dramatically increased expression when compared with pPDGFluc and pCMVIEluc in the two tested cells. In these cells, the activity of PDGF in pCMVIE-PDGF-Luc increased 8 fold in PC12 and 90 fold in MTC17.2 as compared with that from pPDGFluc. The enhancement was far superior to the expression from the simple sum up of PDGF and CMVIE by themselves. Ratios between the levels of expression from pCMVIE-PDGF-Luc and pCMVluc in PC12 and MT C17.2 cells were 0.88 and 2.92

respectively, indicating that the chimeric promoter increased gene expression to nearly or even higher than that of the CMV promoter in these two neuronal-cell lines.

NEURON-SPECIFICITY OF THE CHIMERIC PROMOTER CMVIE-PDGF IN THE BRAIN

[0080] We then investigated if the CMVIE-PDGF promoter could maintain neuronal specificity of PDGF-β promoter. Sections from rats that received either striatal or hippocampal injections of pCMVIE-PDGF-luc and pCMVluc were co-stained with antibodies against both luciferase and a neuronal marker, NeuN. In the hippocampus, the patterns of expression of CMVIE-PDGF-luc and CMV were very different. The CMVIE-PDGF-luc expressing cells were mostly in the granular neuronal cell layer. Immunohistochemical colocalization of the CMVIE-PDGF-luc stained cells with the NeuN marker showed that most of these cells were neuronal (Figure 3). Cell counts demonstrated that 89% of the cells in hippocampus that contained luciferase also contained NeuN (Table 1). In contrast, the CMV-luc expressing cells had a diffuse anatomical distribution spread out from the neuronal cell layers, corresponding to neurons, astrocytes and glial cells. Quantative analysis showed that only 50% of the luciferase stained cells are neurons (Table 1). In the striatum, the CMV-luc stained cells had a diffused distribution, whereas the CMVIE-PDGF-luc were restricted to neurons (Figure 4), same as observed in the hippocampus. Cell counts demonstrated that the proportion of luc expressing neurons for CMVIE-PDGF-Luc was 91%, significantly higher than that for CMV-Luc (48%) (Table 1).

INCREASED IN VIVO GENE EXPRESSION BY USING THE CHIMERIC PROMOTER OF CMVIE-PDGF

[0081] The efficiencies of CMVIE-PDGF, PDGF-β and CMVIE enhancer promoters in inducing luciferase expression in vivo were compared following injection into the rat striatum. Tissue samples were collected from the striatum of each rat brain for luciferase assays. Levels of luciferase activity expressed by each plasmid are presented in Figure 5. Luciferase expression was detected in all of the four plasmid constructs as early as 24 hour post-injection. Expression from CMVIE-

PDGF-luc increased up to 5 days then remained stable until day 14. The expression levels of CMVIE and PDGF-β were low 1 day post-injection and became undetectable after 3 days (data not shown), suggesting the weak activities of these two promoters. Similar to that observed in *in vitro* study, the activity of CMVIE-PDGF was enhanced *in vivo* when compared with CMVIE and PDGF-β promoter.

INCREASED GENE EXPRESSION BY USING THE CHIMERIC PROMOTER OF CMVIE-PDGF IN THE CONTEXT OF VIRAL VECTORS

[0082] Plasmid DNA vectors were used in the above studies. To test whether the chimeric promoter of CMVIE enhancer-PDGF-β promoter may also increase gene expression after insertion into a viral vector, we generated recombinant baculoviruses and adeno-associated viruses containing the chimeric promoter and tested them in cell cultures of rat primary cortex neurons and in rat brain. As shown in Figure 6A, the CMVIE enhancer – PDGF-β promoter significantly increased gene expression, as compared with PDGF-β promoter, by 19-fold when AAV vectors were used and 15-fold when baculovirus vectors were used. The enhancement was far superior to the expression from the simple sum up of PDGF-β promoter and CMVIE enhancer by themselves, as well as to the expression from the CMV promoter. Following injection into the rat striatum, the CMVIE enhancer – PDGF-β promoter in the AAV vectors drove higher levels of in vivo gene expression than the PDGF-β and CMV promoters, displaying a 5-fold increase (Figure 6B).

CLAIMS:

1. A recombinant nucleic acid molecule comprising a neuronal cell specific promoter operably linked to a heterologous enhancer wherein the enhancer is a viral enhancer or promoter and increases the neuronal cell specific transcriptional activity of the promoter.

2. The nucleic acid molecule according to claim 1 wherein the enhancer is RSV promoter, SV40 promoter, or CMV enhancer or promoter.

3. The nucleic acid molecule according to claim 2 wherein the promoter is PDGF β promoter.

4. The nucleic acid molecule according to claim 3 wherein the enhancer is CMVIE enhancer.

5. The nucleic acid molecule according to claim 4 wherein the enhancer comprises the sequence of SEQ ID NO. 9.

6. The nucleic acid molecule according to any one of claims 1 to 5 wherein the promoter comprises the sequence of SEQ ID NO. 10.

7. The nucleic acid molecule according to any one of the preceding claims wherein the promoter is operatively linked downstream to the enhancer.

8. The nucleic acid molecule according to claim 7 comprising the sequence of SEQ ID NO. 11.

9. The nucleic acid molecule according to claim 8 further comprising a coding sequence operably linked to the promoter.

10. The nucleic acid molecule according to claim 9 wherein the coding sequence is a therapeutic gene sequence.

11. An expression vector comprising a nucleic acid molecule according to claim 9.

12. The vector according to claim 11 wherein the vector is a plasmid.

13. The vector according to claim 11 wherein the vector is a virus or is virus- derived.

14. The vector according to claim 13 wherein the vector is a baculovirus or adeno- associated virus.

15. A method of expressing a gene in a neuronal cell in culture, said method comprising transforming a neuronal cell with an expression vector according to claim 11.

16. Use of an expression vector comprising the recombinant nucleic acid molecule of claim 10 in the manufacture of a medicament for treating a neuronal disorder in a subject.

17. The use according to claim 16 wherein the expression vector is mixed with a polymeric gene carrier.

18. The use according to claim 17 wherein the polymeric carrier is a cationic polymer or lipid.

19. The use according to claim 18 wherein the carrier is polyethylenimine.

20. The use according to claim 19 wherein the expression vector is to be administered by direct injection to the central nervous system or the cerebrospinal fluid.

21. The use according to claim 19 wherein the expression vector is to be administered to the central nervous system by stereotaxic microinjection.

22. The use according to any one of claims 19 to 21 wherein the neuronal disorder is stroke, ischemia, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, or a neurogenetic disorder.

23. A transgenic cell or non-human animal comprising the recombinant nucleic acid molecule of any one of claims 8 to 10.

24. A method of increasing the transcriptional activity of a neuronal specific promoter comprising operably linking a heterologous enhancer to the neuronal specific promoter wherein the heterologous enhancer is a viral enhancer or promoter.

25. The method according to claim 24 wherein the enhancer is operably linked upstream to the promoter.

26. The method according to claim 25 wherein the enhancer is RSV promoter, SV40 promoter, or CMV enhancer or promoter.

27. The method according to claim 26 wherein the neuronal specific promoter is human PDGF-β promoter.

28. The method according to claim 27 wherein the enhancer is human CMVIE.

29. A kit comprising a neuronal cell or cell-line, an expression vector of any one of the preceding claims and instructions to stably transform said cells/cell- lines and express recombinant gene product.

30. The use of recombinant molecule of claim 10 in the manufacture of a medicament for the treatment of a neuronal disorder in a subject in need thereof.

31. The use according to claim 30 wherein the neuronal disorder is stroke, ischemia, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, or a neurogenetic disorder.

32. The use of an expression vector of claim 11 in the manufacture of a medicament for the treatment of a neuronal disorder in a subject in need thereof.

33. The use according to claim 32 wherein the expression vector is mixed with a polymeric gene carrier.

34. The use according to claim 33 wherein the polymeric gene carrier is a cationic polymer or lipid.

35. The use according to claim 34 wherein the carrier is polyethylenimine.

36. The use according to any one of claims 30 to 35 wherein the expression vector is to be administered by direct injection to the central nervous system or the cerebrospinal fluid.

37. The use according to claim 36 wherein the administration is to be done by stereotaxic microinjection.

38. The use according to any one of claims 32 to 37 wherein the disorder is stroke, ischemia, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, or a neurogenetic disorder.

39. A recombinant protein expressed in a neuronal cell or cell-line by transforming the cell or cell-line with the vector of claim 11 and allowing the transformed cell or cell line to express the recombinant protein.

40. Use of the recombinant protein according to claim 39 in the manufacture of a medicament for the treatment of neural disorders.

41. Use according to claim 40 wherein the disorder is a stroke, ischemia, epilepsy, head and spinal cord trauma, Parkinson's disease, Huntington's disease, Alzheimer disease, amyotrophic lateral sclerosis, or aneurogenetic disorder.

42. A system for increasing transcriptional activity in a neuronal cell or cell-line comprising a neuronal cell-specific promoter operably linked downstream to a heterologous enhancer as substantially described herein.

SEQUENCE LISTING

<110> Wang, Shu
Liu, Beihui
Wang, Xu

<120> A Promoter Construct And Its Use In Neuronal Gene Transfer

<130> 93231-2

<160> 11

<170> PatentIn version 3.2

<210> 1
<211> 26
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 1
attcggtacc cctgggtcga cattga 26

<210> 2
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 2
caacgagctc accatggtaa tagcgatg 28

<210> 3
<211> 32
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 3
attaggtacc cgatgtacgg gccagatata cg 32

<210> 4
<211> 32
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 4

taataagctt actagtggat ccgagctcgg ta 32

<210> 5
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 5
aattgagctc ctagaggatc cacagtct 28

<210> 6
<211> 29
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 6
cagcaagctt ttcagttcct cgactctag 29

<210> 7
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 7
attgctcaac agtatgggca 20

<210> 8
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 8
cgaagaagga gaatagggtt g 21

<210> 9
<211> 387
<212> DNA
<213> Cytomegalovirus

<220>
<221> misc_feature
<223> cytomegalovirus immediate early enhancer
<400> 9
cctgggtcga cattgattat tgactagtta ttaatagtaa tcaatacggg gtcattagtt 60

catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc gcctggctga 120
ccgcccaacg acccccgccc attgacgtca ataatgacgt atgttcccat agtaacgcca 180
atagggactt tccattgacg tcaatgggtg gactatttac ggtaaactgc ccacttggca 240
gtacatcaag tgtatcatat gccaagtacg cccccctattg acgtcaatga cggtaaatgg 300
cccccctggca ttatgcccag tacatgacct tatgggactt tctacttggc agtacatcta 360
cgtattagtc atcgctatta ccatggt 387

<210> 10
<211> 1488
<212> DNA
<213> human

<220>
<221> misc_feature
<223> human platelet-derived growth factor Beta-chain promoter

<400> 10
ctagaggatc cacagtctcc tgagtagctg ggactacagg agcttgttac cacacccagc 60
tccagtttat aaattcatct ccagtttata aaggaggaaa ccgaggtact gagaggttaa 120
aaaaccttcc tgcagacact tgtccagcaa gtggccactc caggatttgg accaaggtga 180
tgtgtcttca ggctgtgtct ctgccactgt gccacgctgc tgggtggtag gcagcagtgg 240
gtgggtgcct gcagtggtct gtaaagacca cctgagatgt ccttcctcct ctgttccacc 300
ctgtccaggt ccaagaagac agtctatgaa gagagagcag gtgtgactct ctcagtgtgc 360
tcctctgtga gaagcaggct gacatcccaa agggaagggc ggataacaga gacagtgcaa 420
gcggaggaga tgagggtgcc tcaaagccgg gaggctgggt gatgcaggag cctgcgtgtc 480
ccgaggggggg tgctgggccc agtgtgagta cgtgtgactg tgactgagac agtgtgactg 540
ctgaaggcag ggacacagca gctccctgac tgggggcaga aggcgttaac tgtgtgaagg 600
ctggttgtgg gtgggtgggc tctgggcctc gaacccgggg gctgagggag atagtaaaca 660
gcagggtgac tgacgggaag atcatgttgg tagccctgcg aagatgctgc agggctgtgg 720
gggtttgtgt gactttgcag ttcaacaaat tcaaattcag ccaacgctgg cagggcctgt 780
tgtgccaggc aaccagctag gaggaggaga ctcggaccca gcttgcagct gaagggcgct 840
ggctgccggg ttctgtgggt tcaccttgcg gtgtcttccc ttgctaacac tgagtcctta 900
caatagcccc atctccaggt tgaggctaga tggaggggac agagggaagt gacttgccca 960
aggtgaccca agctcccgag tgccagggca ggatctgaat tcaggctctc agactgcaga 1020
gcctgagtcc ctccctgcca tgcctgtgcc agggtggaaa tgtctggtcc tggaggggag 1080
cgtggactcc tggccttggc tctggagaca tccccctaga ccacgtgggc tcctaacctg 1140
tccatggtca ctgtgctgag gggcgggacg gtgggtcacc cctagttctt ttttccccag 1200
ggccagattc atggactgaa gggttgctcg gctctcagag acccccctaag cgccccgccc 1260
tggccccaag ccctcccccа gctcccgcgt ccccccccctc ctggcgctga ctccgggcca 1320
gaagaggaaa ggctgtctcc acccacctct cgcactctcc cttctccttt ataaaggccg 1380
gaacagctga aagggtggca acttctcctc ctgcagccgg gagcggcctg cctgcctccc 1440
tgcgcacccg cagcctcccc cgctgcctcc ctagagtcga ggaactaa 1488

<210> 11
<211> 1881
<212> DNA
<213> Artificial

<220>
<223> CMVIE-PDGF-Beta chimeric promoter

<400> 11
cctgggtcga cattgattat tgactagtta ttaatagtaa tcaatacggg gtcattagtt 60
catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc gcctggctga 120
ccgcccaacg acccccgccc attgacgtca ataatgacgt atgttcccat agtaacgcca 180
atagggactt tccattgacg tcaatgggtg gactatttac ggtaaactgc ccacttggca 240
gtacatcaag tgtatcatat gccaagtacg cccccctattg acgtcaatga cggtaaatgg 300
cccccctggca ttatgcccag tacatgacct tatgggactt tctacttggc agtacatcta 360
cgtattagtc atcgctatta ccatggtgag ctcctagagg atccacagtc tcctgagtag 420

```
ctgggactac aggagcttgt taccacaccc agctccagtt tataaattca tctccagttt   480
ataaaggagg aaaccgaggt actgagaggt taaaaaacct tcctgcagac acttgtccag   540
caagtggcca ctccaggatt tggaccaagg tgatgtgtct tcaggctgtg tctctgccac   600
tgtgccacgc tgctgggtgg taggcagcag tgggtgggtg cctgcagtgg tctgtaaaga   660
ccacctgaga tgtccttcct cctctgttcc accctgtcca ggtccaagaa gacagtctat   720
gaagagagag caggtgtgac tctctcagtg tgctcctctg tgagaagcag gctgacatcc   780
caaagggaag ggcggataac agagacagtg caagcggagg agatgagggt gcctcaaagc   840
cgggaggctg ggtgatgcag gagcctgcgt gtcccgaggg gggtgctggg cccagtgtga   900
gtacgtgtga ctgtgactga gacagtgtga ctgctgaagg cagggacaca gcagctccct   960
gactgggggc agaaggcgtt aactgtgtga aggctggttg tgggtgggtg ggctctgggc  1020
ctcgaacccg ggggctgagg gagatagtaa acagcagggt gactgacggg aagatcatgt  1080
tggtagccct gcgaagatgc tgcagggctg tgggggtttg tgtgactttg cagttcaaca  1140
aattcaaatt cagccaacgc tggcagggcc tgttgtgcca ggcaaccagc taggaggagg  1200
agactcggac ccagcttgca gctgaagggc gctggctgcc gggttctgtg ggttcacctt  1260
gcggtgtctt cccttgctaa cactgagtcc ttacaatagc cccatctcca ggttgaggct  1320
agatggaggg gacagaggga agtgacttgc ccaaggtgac ccaagctccc gagtgccagg  1380
gcaggatctg aattcaggct ctcagactgc agagcctgag tccctccctg ccatgcctgt  1440
gccagggtgg aaatgtctgg tcctggaggg gagcgtggac tcctggcctt ggctctggag  1500
acatcccccc agaccacgtg ggctcctaac ctgtccatgg tcactgtgct gaggggcggg  1560
acggtgggtc acccctagtt ctttttttccc cagggccaga ttcatggact gaagggttgc  1620
tcggctctca gagacccccc aagcgccccg ccctggcccc aagccctccc ccagctcccg  1680
cgtcccccccc ctcctggcgc tgactccggg ccagaagagg aaaggctgtc tccacccacc  1740
tctcgcactc tcccttctcc tttataaagg ccggaacagc tgaaagggtg gcaacttctc  1800
ctcctgcagc cgggagcggc ctgcctgcct ccctgcgcac ccgcagcctc ccccgctgcc  1860
tccctagagt cgaggaacta a                                            1881
```